2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresFemaleHumansOvarian NeoplasmsParityPregnancyRetrospective StudiesConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survivalHigh pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharaoh P, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0977-a.2021. PMID: 34789471, PMCID: PMC9281656, DOI: 10.1158/1055-9965.epi-21-0977.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Ovarian EpithelialFemaleHealth BehaviorHumansInflammationMiddle AgedOvarian NeoplasmsProportional Hazards ModelsRisk AssessmentConceptsOvarian cancer survivalCox proportional hazards modelProportional hazards modelCancer survivalOvarian cancerRisk scoreHazards modelNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useMenopausal hormone therapy useEnvironmental tobacco smoke exposureInvasive epithelial ovarian cancerHormone therapy usePelvic inflammatory diseaseInflammation-related factorsPolycystic ovarian syndromeTobacco smoke exposureBody mass indexRisk of deathEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancer diagnosisHigh death rateAspirin useOvarian syndrome
2021
Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Ovarian EpithelialCase-Control StudiesContraceptive Agents, HormonalFemaleHumansMedroxyprogesterone AcetateMiddle AgedOvarian NeoplasmsProgestinsRisk AssessmentConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, InducedAbortion, SpontaneousCarcinoma, Ovarian EpithelialCase-Control StudiesFemaleHumansOvarian NeoplasmsParityPregnancyRiskUnited KingdomUnited StatesConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancy